Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$1.13
-2.2%
$1.51
$0.78
$2.48
$235.80M0.944.04 million shs942,607 shs
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
$5.93
-5.0%
$7.49
$2.58
$11.67
$263.06M1.76120,470 shs36,543 shs
Forian Inc. stock logo
FORA
Forian
$2.81
+5.2%
$2.92
$1.85
$4.15
$87.50M1.1123,326 shs6,419 shs
Tabula Rasa HealthCare, Inc. stock logo
TRHC
Tabula Rasa HealthCare
$10.50
$10.45
$3.15
$10.50
$284.13M1.57225,500 shsN/A
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
0.00%-10.85%-15.44%-20.14%-0.86%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
+9.47%+5.23%-1.27%-28.11%+123.66%
Forian Inc. stock logo
FORA
Forian
+4.14%+1.47%+4.53%+5.32%+16.14%
Tabula Rasa HealthCare, Inc. stock logo
TRHC
Tabula Rasa HealthCare
0.00%0.00%0.00%0.00%+75.59%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
4.1367 of 5 stars
3.54.00.04.02.60.80.6
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
2.1451 of 5 stars
3.52.00.00.02.33.30.0
Forian Inc. stock logo
FORA
Forian
2.8544 of 5 stars
3.54.00.00.01.51.71.3
Tabula Rasa HealthCare, Inc. stock logo
TRHC
Tabula Rasa HealthCare
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
3.00
Buy$5.00344.44% Upside
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
3.00
Buy$16.50178.25% Upside
Forian Inc. stock logo
FORA
Forian
3.00
Buy$7.67172.84% Upside
Tabula Rasa HealthCare, Inc. stock logo
TRHC
Tabula Rasa HealthCare
2.00
HoldN/AN/A

Current Analyst Ratings

Latest TRHC, FORA, EPIX, and AKBA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2024
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$17.00 ➝ $17.00
4/4/2024
Forian Inc. stock logo
FORA
Forian
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
3/28/2024
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$5.00 ➝ $6.00
3/15/2024
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
(Data available from 5/21/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$194.62M1.21N/AN/A($0.16) per share-7.03
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/AN/AN/AN/A$3.30 per shareN/A
Forian Inc. stock logo
FORA
Forian
$20.49M4.27N/AN/AN/A
Tabula Rasa HealthCare, Inc. stock logo
TRHC
Tabula Rasa HealthCare
$299.52M0.95N/AN/A($2.10) per share-5.00

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$51.92M-$0.23N/AN/AN/A-22.99%N/A-18.01%8/23/2024 (Estimated)
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$26.58M-$0.63N/AN/AN/AN/A-19.46%-18.96%8/13/2024 (Estimated)
Forian Inc. stock logo
FORA
Forian
N/A$0.1028.10N/AN/AN/AN/A8/8/2024 (Estimated)
Tabula Rasa HealthCare, Inc. stock logo
TRHC
Tabula Rasa HealthCare
-$147.51M-$3.85N/AN/AN/A-28.23%N/A-8.80%N/A

Latest TRHC, FORA, EPIX, and AKBA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024Q1 2024
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$0.09-$0.09N/A-$0.09$41.13 million$32.61 million    
3/28/2024Q4 2023
Forian Inc. stock logo
FORA
Forian
N/A-$0.01-$0.01-$0.06$5.72 million$5.37 million
3/14/2024Q4 2023
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$0.04-$0.04N/AN/A$55.64 million$56.20 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
N/AN/AN/AN/AN/A
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/AN/AN/AN/AN/A
Forian Inc. stock logo
FORA
Forian
N/AN/AN/AN/AN/A
Tabula Rasa HealthCare, Inc. stock logo
TRHC
Tabula Rasa HealthCare
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
N/A
1.70
1.31
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/A
32.89
32.89
Forian Inc. stock logo
FORA
Forian
N/AN/AN/A
Tabula Rasa HealthCare, Inc. stock logo
TRHC
Tabula Rasa HealthCare
N/A
1.57
1.47

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
33.92%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
75.12%
Forian Inc. stock logo
FORA
Forian
19.25%
Tabula Rasa HealthCare, Inc. stock logo
TRHC
Tabula Rasa HealthCare
61.88%

Insider Ownership

CompanyInsider Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
3.84%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
14.70%
Forian Inc. stock logo
FORA
Forian
31.30%
Tabula Rasa HealthCare, Inc. stock logo
TRHC
Tabula Rasa HealthCare
30.30%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
167209.60 million201.55 millionOptionable
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
5044.36 million37.84 millionOptionable
Forian Inc. stock logo
FORA
Forian
10231.14 millionN/AOptionable
Tabula Rasa HealthCare, Inc. stock logo
TRHC
Tabula Rasa HealthCare
1,02727.06 million18.86 millionOptionable

TRHC, FORA, EPIX, and AKBA Headlines

Recent News About These Companies

Daniel C Lubin's Net Worth
Tabula Rasa HealthCare: Other Events
Tabula Rasa HealthCare Inc. News
Why Are Tabula Rasa HealthCare Shares Moving Higher Today?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Akebia Therapeutics logo

Akebia Therapeutics

NASDAQ:AKBA
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
ESSA Pharma logo

ESSA Pharma

NASDAQ:EPIX
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Forian logo

Forian

NASDAQ:FORA
Forian Inc. provides software and information solutions, proprietary data driven insights, and predictive analytics to optimize and measure the operational, clinical, and financial performance of its life science and healthcare customers. It operates through three segments: Information & Software, Services, and Other. The company's products include BioTrack, a vertically integrated point of sale, manufacturing, delivery, and cultivator software solution for dispensaries, cultivators, manufacturers, and distributors; and Cannalytics, a Software as a Service based analytics solution that provides customers with a presentation of business performance. Its products also comprise BioTrack seed-to-sale compliance traceability platform, which is used to manage the tracking and tracing of various cannabis products from cultivation to sale; and BioTrack State Traceability & Enforcement Monitoring System to ensure transparency and accountability throughout cannabis supply chain. In addition, the company offers security monitoring and web marketing services. Forian Inc. was incorporated in 2020 and is headquartered in Newtown, Pennsylvania. Forian Inc.
Tabula Rasa HealthCare logo

Tabula Rasa HealthCare

NASDAQ:TRHC
Tabula Rasa HealthCare, Inc. operates as a healthcare technology company in the United States. The company operates in two segments, CareVention HealthCare and MedWise HealthCare. It offers EireneRx, a cloud-based medication decision-support and e-prescribing platform to access patient medication-related information; and MedWise Risk Score, a medication risk stratification technology for identification of patients in need of clinical intervention. The company also provides TruChart that offers electronic health records (EHR), care coordination, and financial management in one program allowing Programs of All-Inclusive Care for the Elderly (PACE) to track measurable outcomes in defined timeframes for the populations they serve; and PACElogic, which delivers sharable workflows comprising EHR, customer relationship management, claims adjudication, electronic data interchange, care management, coordination and planning, integration with community-based providers, and various federal and state that requires reporting. In addition, it provides clinical pharmacist collaboration, prescription fulfillment and adherence packaging, and pharmacy benefit management services, as well as health plan management services, including risk adjustment and third-party administrator services. As of December 31, 2022, it served approximately 150 healthcare organizations. The company provides cloud-based software applications to assist prescribers and pharmacists. Tabula Rasa HealthCare, Inc. was founded in 2009 and is headquartered in Moorestown, New Jersey. As of November 3, 2023, Tabula Rasa HealthCare, Inc. operates as a subsidiary of Exact Care Pharmacy, LLC.